|
|
Post by afrezzamiracle on Jul 8, 2018 22:24:10 GMT -5
Management needs to provide clarity on what happened to our promising compounds in these blockbuster categories.
|
|
|
|
Post by mango on Jul 8, 2018 22:37:55 GMT -5
Management needs to provide clarity on what happened to our promising compounds in these blockbuster categories. I think the MannKind/Torrey Pines pain formulation was a Bucket #4 category last I saw š and Epi is 'Available for license' via website. |
|
|
|
Post by peppy on Jul 9, 2018 7:04:49 GMT -5
Not sure where this came from considering the commentary.  |
|
|
|
Post by matt on Jul 9, 2018 7:52:08 GMT -5
Management needs to provide clarity on what happened to our promising compounds in these blockbuster categories. On epi, Mylan got so much bad press that several other companies jumped in with competitive products, the latest of which is Novartis. Avoiding a space that has rapidly become crowded with deep-pocketed competitors was probably the right call. Big pharmas set on entering a space can move more quickly than you can imagine and MNKD simply doesn't have the money or the infrastructure to compete with a determined competitor. Palonosetron is a nice niche product, but not one that will generate lots of excitement. The normal route of administration is IV, but so is the route of administration of chemotherapy drugs. If the patient already has an IV drip, adding an anti-emetic before or after the chemotherapeutic is not a big deal so it is not clear what benefit an inhaled formulation adds. Certainly it can help several hours post chemo, but that market would be limited and might not justify the investment required. Pain is an interesting category, but one where FDA has become very conservative in approving new formulations and agents. Even "abuse resistant" formulations are getting shot down at the advisory committee stage so anything new that does not require a needle to administer is going to be a hard sell to the regulators. MNKD would have to convince a skeptical medical community that the improved ease of administration for an existing drug outweighs the potential for increased abuse. If MNKD can find the right agent, likely a totally new drug that does not lend itself to oral administration and which has limited potential for abuse, then there is still promise in the pain sector. |
|
|
|
Post by afrezzamiracle on Jul 9, 2018 10:22:43 GMT -5
Anti pain is the Holy Grail. I hope we havenāt given up on that one!
|
|
|
|
Post by babaoriley on Jul 10, 2018 12:18:46 GMT -5
The Holy Grail for technosphere is something that would cause a person to forget about the money they've invested in MannKind for a period of, say, a calendar quarter at a time. 
I believe the FDA would quickly grant compassionate use for such a formulation.
|
|
|
|
Post by mytakeonit on Jul 10, 2018 13:20:30 GMT -5
Click !
|
|
